Sponsors (12)
The bill increases national security by restricting export of sensitive synthetic genetic data and creates regulatory predictability, but it does so at the cost of higher compliance burdens and potential delays to international research collaboration and biotech innovation.
Scientists, biotech firms, and the public face reduced risk that sensitive synthetic genetic data and dual‑use bio-designs will be accessed or exploited by hostile foreign governments or actors, strengthening U.S. national security.
Establishes a clear legal framework and a one-year deadline for Commerce to regulate potentially high‑risk bio-design data, improving predictability for exporters and regulators.
Exempts information already covered by existing rules (15 C.F.R. § 734.3(b)), helping avoid duplicative controls on publicly available or benign information.
Researchers and students collaborating internationally could face delays, reduced data sharing, and weakened scientific partnerships, slowing biomedical research and innovation.
Academic and commercial biotech organizations will incur higher compliance costs and potential delays exporting sequence files or designs to collaborators in covered countries, which can slow projects and increase operating expenses.
Tighter rules and unclear definitions (e.g., scope of 'digital sequence' and 'foreign entity of concern') create regulatory uncertainty and administrative burdens that raise legal/compliance costs for startups, labs, and government agencies.
Based on analysis of 3 sections of legislative text.
Requires federal export licenses for digital human‑ or AI‑designed synthetic DNA/RNA sequences sent to foreign entities of concern, with a one‑year implementation deadline.
Official title: To restrict the export to foreign entities of concern of United States intellectual property and sensitive information related to synthetic biology, and for other purposes.
Introduced December 11, 2025 by Warren Davidson · Last progress December 11, 2025
Requires federal export licenses for digital sequences of synthetic DNA or RNA that are designed by humans or artificial intelligence before they are exported, reexported, or transferred in‑country to specified foreign entities of concern. Directs the Secretary to put the licensing requirement into effect within one year and defines covered terms and covered foreign entities. Targets transfers to governments, organizations, or persons tied to foreign countries of concern (cross‑referenced to existing statute) and excludes certain materials already exempted by existing regulation. The law frames the measure as a national security step to protect biotechnology intellectual property and sensitive design data from exploitation by foreign adversaries.